The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Sex Is A Major Determinant of Cyp3a4 Expression in Human Liver
Open accessAbstract
Many drugs that are substrates of CYP3A4, the major human drug–metabolizing cytochrome P450 (CYP), show higher clearance in women than in men. Although this effect is believed to be related to drug metabolism, the underlying cause has not been elucidated. We investigated CYP3A4 in a large collection (n = 94) of well–characterized surgical liver samples and found 2–fold higher CYP3A4 levels in female compared with male samples (P < .0001) and a corresponding 50% increase in the CYP3A–dependent N–dealkylation of verapamil (P < .01). This expression difference was not due to preferential induction in women following higher drug exposure because it was even larger in a subgroup not previously exposed to drugs. Higher expression in women was also found for CYP3A4 messenger RNA (mRNA) transcripts, suggesting a pretranslational mechanism. Expression of the pregnane X receptor (PXR), which is crucially involved in CYP3A4 induction by xenobiotics, was strongly correlated to CYP3A4 at the mRNA level in all individuals as well as in the subgroup not exposed to drugs (r = 0.81; P < .0001), but no sex–dependent expression of PXR mRNA was found. The ABC transporter P–glycoprotein, which has been proposed to be implicated in the mechanism of sex–dependent drug clearance, was also not differentially expressed. The influence of drug treatment on expression was examined from patient drug histories, and strong induction of CYP3A4 by carbamazepine and St. John's wort was found. In conclusion, sex, in addition to PXR and drug exposure, is a major factor for CYP3A4 expression in humans, thus explaining many of the previous observations of sex–dependent drug clearance. (Hepatology 2003;38:978-988).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Carbon Monoxide-binding Pigment of Liver Microsomes
Omura, T., & Sato, R. (1964) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)82244-3 · Cited by 11,781
The Carbon Monoxide-binding Pigment of Liver Microsomes
Omura, T., & Sato, R. (1964) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)82245-5 · Cited by 3,489
Shimada, T., Yamazaki, H., Mimura, M., Inui, Y., & Guengerich, F. P. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22379-5 · Cited by 2,785
Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics
Evans, W. E., & Relling, M. V. (1999) · Science · doi:10.1126/science.286.5439.487 · Cited by 2,475
Kuehl, P., Zhang, J., Lin, Y., Lamba, J., Assem, M., Schuetz, J., Watkins, P. B., Daly, A., Wrighton, S. A., Hall, S. D., et al. (2001) · Nature Genetics · doi:10.1038/86882 · Cited by 2,162
CYTOCHROME P-450 3A4: Regulation and Role in Drug Metabolism
Guengerich, F. P. (1999) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.39.1.1 · Cited by 1,267
Wacher, V. J., Wu, C., & Benet, L. Z. (1995) · Molecular Carcinogenesis · doi:10.1002/mc.2940130302 · Cited by 857
The genetic determinants of the CYP3A5 polymorphism
Hustert, E., Haberl, M., Burk, O., Wolbold, R., He, Y.-Q., Klein, K., Nuessler, A. C., Neuhaus, P., Klattig, J., Eiselt, R., et al. (2001) · Pharmacogenetics · doi:10.1097/00008571-200112000-00005 · Cited by 673
Self-citationThummel, K. E., O'Shea, D., Paine, M. F., Shen, D. D., Kunze, K. L., Perkins, J. D., & Wilkinson, G. R. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90177-0 · Cited by 617
St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4
Dürr, D. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.112240 · Cited by 584
Cited by
Zanger, U. M., & Schwab, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.007 · Cited by 4,169
“3, CYP3A4 shows significant activity and expression differences in females versus males (Wolbold et al., 2003; Cotreau et al., 2005; Lamba et al., 2010).”
BackgroundSelf-citationSex Differences in the Expression of Hepatic Drug Metabolizing Enzymes
Waxman, D. J., & Holloway, M. G. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.056705 · Cited by 815
Cobbina, E., & Akhlaghi, F. (2017) · Drug Metabolism Reviews · doi:10.1080/03602532.2017.1293683 · Cited by 653
Cytochrome P450-mediated metabolism of estrogens and its regulation in human
Tsuchiya, Y., Nakajima, M., & Yokoi, T. (2005) · Cancer Letters · doi:10.1016/j.canlet.2004.10.007 · Cited by 616
Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation
Zanger, U. M., Turpeinen, M., Klein, K., & Schwab, M. (2008) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-008-2291-6 · Cited by 593
Self-citationIntronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs
Wang, D., Guo, Y., Wrighton, S. A., Cooke, G. E., & Sadee, W. (2011) · The Pharmacogenomics Journal · doi:10.1038/tpj.2010.28 · Cited by 505
Growth Hormone Regulation of Sex-Dependent Liver Gene Expression
Waxman, D. J., & O’Connor, C. (2006) · Molecular Endocrinology · doi:10.1210/me.2006-0007 · Cited by 458
Nies, A. T., Koepsell, H., Winter, S., Burk, O., Klein, K., Kerb, R., Zanger, U. M., Keppler, D., Schwab, M., & Schaeffeler, E. (2009) · Hepatology · doi:10.1002/hep.23103 · Cited by 387
Self-citationPARKINSON, A. (2004) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2004.01.010 · Cited by 386
Molecular mechanisms underlying chemical liver injury
Gu, X., & Manautou, J. E. (2012) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399411002110 · Cited by 381
Chapter 1 Gender Differences in Pharmacological Response
Anderson, G. D. (2008) · International Review of Neurobiology · doi:10.1016/s0074-7742(08)00001-9 · Cited by 347
Sex Differences in Drug Disposition
Soldin, O. P., Chung, S. H., & Mattison, D. R. (2011) · BioMed Research International · doi:10.1155/2011/187103 · Cited by 341
Renal Transporters in Drug Development
Morrissey, K. M., Stocker, S. L., Wittwer, M. B., Xu, L., & Giacomini, K. M. (2013) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011112-140317 · Cited by 324
Anderson, G. D. (2005) · Journal of Women's Health · doi:10.1089/jwh.2005.14.19 · Cited by 321
Gender differences in the effects of cardiovascular drugs
Tamargo, J., Rosano, G., Walther, T., Duarte, J., Niessner, A., Kaski, J., Ceconi, C., Drexel, H., Kjeldsen, K., Savarese, G., et al. (2017) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvw042 · Cited by 317
Wolking, S., Schaeffeler, E., Lerche, H., Schwab, M., & Nies, A. T. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0267-1 · Cited by 309
Self-citationThe Influence of Age and Sex on the Clearance of Cytochrome P450 3A Substrates
Cotreau, M. M., von Moltke, L. L., & Greenblatt, D. J. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544010-00002 · Cited by 292
Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases
Jochmann, N., Stangl, K., Garbe, E., Baumann, G., & Stangl, V. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi397 · Cited by 272
Albermann, N., Schmitz-Winnenthal, F. H., Z’graggen, K., Volk, C., Hoffmann, M. M., Haefeli, W. E., & Weiss, J. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.06.018 · Cited by 270
Nies, A. T., Niemi, M., Burk, O., Winter, S., Zanger, U. M., Stieger, B., Schwab, M., & Schaeffeler, E. (2013) · Genome Medicine · doi:10.1186/gm405 · Cited by 265
Self-citationThe Current State of Knowledge on Age, Sex, and Their Interactions on Clinical Pharmacology
Schwartz, J. B. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100226 · Cited by 256
von Richter, O., Burk, O., Fromm, M. F., Thon, K. P., Eichelbaum, M., & Kivistö, K. T. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.10.008 · Cited by 255
Self-citationAchour, B., Barber, J., & Rostami-Hodjegan, A. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.058834 · Cited by 212
Yu, K., Geng, X., Chen, M., Zhang, J., Wang, B., Ilic, K., & Tong, W. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.056267 · Cited by 150
Holloway, M. G., Miles, G. D., Dombkowski, A. A., & Waxman, D. J. (2008) · Molecular Endocrinology · doi:10.1210/me.2007-0564 · Cited by 108
Christian, C. A., Reddy, D. S., Maguire, J., & Forcelli, P. A. (2020) · Pharmacological Reviews · doi:10.1124/pr.119.017392 · Cited by 105
Ma, L., Barker, J., Zhou, C., Li, W., Zhang, J., Lin, B., Foltz, G., Küblbeck, J., & Honkakoski, P. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.02.054 · Cited by 83
Differences in cytochrome p450 enzyme expression and activity in fetal and adult tissues
Robinson, J. F., Hamilton, E. G., Lam, J., Chen, H., & Woodruff, T. J. (2020) · Placenta · doi:10.1016/j.placenta.2020.07.009 · Cited by 51
Impact of Statin Use on Dementia Incidence in Elderly Men and Women with Ischemic Heart Disease
Kim, M.-Y., Jung, M., Noh, Y., Shin, S., Hong, C. H., Lee, S., & Jung, Y.-S. (2020) · Biomedicines · doi:10.3390/biomedicines8020030 · Cited by 23
Lombrea, A., Romanescu, M., Jianu, N., Andor, M., Suciu, M., Man, D. E., Danciu, C., Dehelean, C. A., & Buda, V. (2023) · Pharmaceuticals · doi:10.3390/ph16060853 · Cited by 8
“Specifically, atorvastatin and simvastatin are primarily metabolized by CYP3A4, which is expressed at a 2-fold greater level in women than in males, resulting in a quicker and more thorough statin metabolism and subsequently a decreased activity relative to men [76].”
Background
Metadata
- Authors
- Wolbold, R., Klein, K., Burk, O., Nüssler, A. K., Neuhaus, P., Eichelbaum, M., Schwab, M., & Zanger, U. M.
- Venue
- Hepatology
- Published
- 2003-10
- Volume
- 38
- Issue
- 4
- Pages
- 978-988
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W1997538585
- Cited by
- 529
- References
- 57
- FWCI
- 18.22
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.